Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Asiatic Laboratories's net income from continuing operations for the
six
months ended in . 20 was BDT0.00 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.
Asiatic Laboratories Net Income From Continuing Operations Historical Data
* Premium members only.
The historical data trend for Asiatic Laboratories's Net Income From Continuing Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asiatic Laboratories Net Income From Continuing Operations Chart
Asiatic Laboratories Net Income From Continuing Operations Calculation
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income From Continuing Operations for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income From Continuing Operations of BDT0.00 Mil mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a Net Income From Continuing Operations of BDT0.00 Mil as of . 20. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Asiatic Laboratories and its competitors.
Is Asiatic Laboratories' Net Income From Continuing Operations too high?
Asiatic Laboratories' current Net Income From Continuing Operations is BDT0.00 Mil. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Net Income From Continuing Operations compare to ZTS and UTHR?
Asiatic Laboratories' Net Income From Continuing Operations of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Asiatic Laboratories and its competitors. Asiatic Laboratories's current Net Income From Continuing Operations is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Net Income From Continuing Operations of BDT0.00 Mil. The current Net Income From Continuing Operations is BDT0.00 Mil. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Net Income From Continuing Operations is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score
Get the complete analysis for DHA:ASIATICLAB
Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ASIATICLAB has been successfully added to your 
